The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.v

Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

The DLCO/KCO are impacted more often than volumes and flows. Changes concomitant with the administration of chemotherapy, and tend to resolve after completion of treatment. Residual defect may persist longterm

Publications

Keikhaei B, Bahadoram M, Keikha A, Bahadoram S, Hassanzadeh S, Mahmoudian-Sani MR

Late side effects of cancer treatment in childhood cancer survivors.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022 Mar 15;;10781552221087611 — 2022 Mar 15 — 10781552221087611

Keldsen N, Jöhnk ML, Ejlersen JA

Impairment of Lung Function During Adjuvant Oxaliplatin Treatment in Patients with Colorectal Cancer: A Prospective Trial.

Current drug safety 2016;11;215-21 — 2016 — 215-21

Patel A, Weismann C, Weiss P, Russell K, Bazzy-Asaad A, Kadan-Lottick NS

Association between right ventricular dysfunction and restrictive lung disease in childhood cancer survivors as measured by quantitative echocardiography.

Pediatric blood & cancer 2014 Nov;61;2059-64 — 2014 Nov — 2059-64

Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ

Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.

Chest 2009 Jun;135;1588-1595 — 2009 Jun — 1588-1595

Myers JN, O'neil KM, Walsh TE, Hoffmeister KJ, Venzon DJ, Johnson BE

The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation.

Chest 2005 Nov;128;3261-8 — 2005 Nov — 3261-8

Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, Sklar C, Robison LL,

Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study.

Cancer 2002 Dec 01;95;2431-41 — 2002 Dec 01 — 2431-41

Dimopoulou I, Galani H, Dafni U, Samakovii A, Roussos C, Dimopoulos MA

A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.

Cancer 2002 Jan 15;94;452-8 — 2002 Jan 15 — 452-8

Marina NM, Greenwald CA, Fairclough DL, Thompson EI, Wilimas JA, Mackert PW, Hudson MM, Stokes DC, Bozeman PM

Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarba

Cancer 1995 Apr 01;75;1706-11 — 1995 Apr 01 — 1706-11